Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bimatoprost
Drug ID BADD_D00274
Description Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.[L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.[L4894]
Indications and Usage For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Marketing Status Prescription; Discontinued
ATC Code S01EE03
DrugBank ID DB00905
KEGG ID D02724
MeSH ID D000069580
PubChem ID 5311027
NDC Product Code 72266-139; 0023-3616; 82187-1001; 68083-439; 50383-912; 71052-276; 40016-005; 24002-0021; 70069-401; 0781-6206; 65129-1206; 42571-128; 62332-511; 76397-016; 73309-002; 46144-328; 54893-0009; 57741-3000; 55679-113; 82231-102; 73309-022; 0023-3205; 60505-0583; 68180-429; 50383-908; 63190-0290; 70069-402; 68245-0004; 65035-130; 72266-140; 70069-403; 62332-507; 54245-7036; 0023-9652; 68083-295; 65727-025; 72266-241; 12079-1067; 68083-296; 38779-3066; 61556-070
Synonyms Bimatoprost | Latisse | Lumigan | AGN 192024 | 192024, AGN
Chemical Information
Molecular Formula C25H37NO4
CAS Registry Number 155206-00-1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain upper07.01.05.003--
Abnormal sensation in eye06.01.01.0010.003013%Not Available
Accommodation disorder06.02.04.0010.000861%Not Available
Acne23.02.01.0010.002152%Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Asthenopia06.01.01.0020.001291%Not Available
Asthma22.03.01.002; Available
Atrial fibrillation02.03.03.002--
Basal cell carcinoma23.08.02.001; Available
Bladder pain20.02.02.001--Not Available
Blepharal pigmentation06.06.04.014; Available
Blepharitis23.03.04.012; Available
Blepharospasm17.17.02.001; Available
Blindness17.17.01.003; Available
Blindness transient17.17.01.004; Available
Blindness unilateral17.17.01.016; Available
Blister23.03.01.001; Available
Blood creatinine increased13.13.01.004--
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Bradycardia02.03.02.002--Not Available
Breast cancer21.05.01.003; Available
Burning sensation08.01.09.029; Available
The 1th Page    1 2 3 4 5    Next   Last    Total 8 Pages